NeoGenomics CFO Secures $9.49‑Option Grant Amid RaDaR ST Rollout, Hinting at Management’s Bet on Diagnostic Growth
NeoGenomics CFO Abhishek Jain’s March 2026 option grant signals confidence in the new RaDaR ST platform—could boost shareholder value if the company turns profitable.
3 minutes to read